Partnership Between CytoMed and SunAct for Cancer Trials
CytoMed Therapeutics Limited (NASDAQ: GDTC), a biopharmaceutical company based in Singapore, proudly announces a significant collaboration with SunAct Cancer Institute in India. This partnership marks the initiation of a Phase 2 clinical trial focused on a groundbreaking cancer treatment. The trial will primarily evaluate the safety and efficacy of CytoMed's allogeneic gamma delta T cells in combating solid tumors, which could potentially revolutionize treatment approaches.
Innovative Approaches to Cancer Therapy
The aim of this collaboration is to accelerate the utilization and development of cutting-edge cell-based immunotherapy. This approach promises to deliver more affordable treatment alternatives to cancer patients in India, supporting broader access to necessary therapies. By leveraging SunAct's extensive expertise and state-of-the-art facilities, together with CytoMed's proprietary technology and manufacturing strengths, both organizations aspire to push the boundaries of cancer treatment.
Expert Insights on the Clinical Trial
Dr. Vijay Patil, a notable oncologist affiliated with SunAct, voiced his optimism regarding the potential contributions this study could bring to the global fight against cancer. CytoMed's Chairman, Peter Choo, also expressed enthusiasm, emphasizing the synergy with SunAct’s commitment to effective, affordable cancer therapeutics. This strong alignment in visions lays a solid foundation for mutual success in their endeavors.
Long-term Collaboration Details
The agreement between the two entities is designed for a term spanning five years, during which they will jointly sponsor the clinical trial. CytoMed is set to provide essential scientific and technical support while also producing the investigational gamma delta T cells. This collaborative spirit is crucial as both companies navigate the complexities of clinical research.
Cancer Immunotherapy Advancements in India
This venture occurs amid a broader push in India for advancements in cancer immunotherapy, driven by supportive regulation and research incentives. The Central Drugs Standard Control Organization (CDSCO) of India plays a crucial role in overseeing international clinical trials, ensuring that new therapies meet stringent safety and efficacy standards.
CytoMed's Background and Recent Achievements
Founded in 2018 and spun off from Singapore's Agency for Science, Technology and Research (ASTAR), CytoMed specializes in developing innovative immunotherapies aimed at treating cancer. Concurrently, SunAct Cancer Institute has earned a reputation as a leader in cancer research and treatment, particularly noted for its pioneering CAR T-cell therapy efforts.
Recent Developments and Future Prospects
Recently, CytoMed Therapeutics Limited has also announced the commencement of a Phase I clinical trial for a novel CAR-T cell therapy, referred to as the ANGELICA Trial. This trial, in collaboration with the National University Hospital of Singapore, uses a first-in-class method employing allogeneic chimeric antigen receptor T cells derived from healthy donors. This approach has the potential to enhance efficacy and reduce the costs associated with CAR-T cell therapies significantly.
Investments in Cord Blood Banking
Additionally, CytoMed has made strides in expanding its capabilities by acquiring a licensed cord blood bank in Malaysia through its subsidiary, LongevityBank Pte Ltd. This investment aims to utilize cord blood-derived biologics for research on aging diseases and regenerative medicine, reflecting the company's commitment to innovative healthcare solutions.
Acquisition of New Assets
In line with its strategic growth, CytoMed recently purchased assets from Cellsafe International Sdn Bhd, a Malaysian cord blood bank, for approximately $490,000. This acquisition not only includes a cord blood banking license and cryopreservation equipment but also encompasses over 12,000 cord blood units along with two real estate properties. Such investments aim to broaden the utility of cord blood for treating various conditions, including solid cancers.
Advancements in Stem Cell Technology
Furthermore, CytoMed has been awarded a Malaysian patent for its innovation in utilizing induced pluripotent stem cell (iPSC)-derived hybrid gamma delta Natural Killer T (?? NKT) cells technology. This advancement could potentially target a diverse range of cancers without necessitating genetic editing, which is a significant leap in cancer treatment methodologies. The company's management has received approval to invest in this promising venture, aligning with its overarching goal to create affordable, readily available immune cell therapies for life-threatening diseases, especially cancers.
Frequently Asked Questions
What is the purpose of the clinical trial between CytoMed and SunAct?
The trial aims to evaluate the safety and efficacy of allogeneic gamma delta T cells as a treatment for solid tumors.
How long will the collaboration between CytoMed and SunAct last?
The collaboration is set for a term of five years, during which joint sponsorship of the clinical trial will occur.
What recent advancements have been made by CytoMed?
CytoMed has initiated the ANGELICA Trial and acquired a cord blood bank in Malaysia for research related to regenerative medicine.
Why is the agreement significant for cancer treatment in India?
This partnership aims to provide more affordable, effective treatment options for cancer patients in India, leveraging both companies' strengths.
What technology has CytoMed been patented for?
CytoMed received a patent for iPSC-derived hybrid gamma delta NKT cells technology, which targets various cancers without genetic editing.
